Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Stevanato Group lauches modular, robotic pharma inspection system with AI

By Chris Newmarker | July 8, 2020

Stevanto Group Vision Robot Unit (VRU)

The Vision Robot Unit (VRU) [Image courtesy of Stevanto Group]

The Stevanto Group (Piombino Dese, Italy) announced today that it is launching a modular, robotic inspection system that incorporates AI with accrued machine learning capabilities.

The company boasts that its Vision Robot Unit (VRU) is able to automatically and reliably inspect both cosmetic and particle properties without human intervention.

The VRU has a patent-pending design that incorporates a “plug and play” concept with a freely configurable infeed and outfeed. It’s possible to add multiple vision inspection units to increase throughput. The no glass-to-glass inspection process mitigates the likelihood of product damage or breakage.

AI technology enables the VRU to improve inspection performance, quickly reacting to changing product characteristics including active ingredient variations, differing fill levels and different containers. It can adapt and learn.

The Stevanto Group describes the VRI as ideal for a broad array of applications in the pharma development and manufacturing landscape, including biotech products such as monoclonal antibodies (mAbs), vaccines and lyophilized drugs. Suitable for inspecting high-value products, the machine can be employed both in laboratory settings and for small batch production.

“Pharmaceutical companies are increasingly looking for flexible solutions incorporating the most advanced technologies,” said Raffaele Pace, engineering head of operations at Stevanato Group. “Our novel Vision Robot Unit is a breakthrough solution, as it addresses some of today’s operational challenges by providing a fully automatic and extremely accurate control process for complex drugs.”

Tell Us What You Think! Cancel reply

Related Articles Read More >

Novartis logo
Novartis mulls sale of $25 billion Sandoz generics arm
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Fujifilm Diosynth Technologies
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
Zantac
First Zantac trial slated for February 2023

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards